Status note Phase 3 trial in mild to moderate probable AD (NCT04669028) topline announced Nov 29, 2023; securities class action re NM101 Phase 3/AD trial pending (class certification briefing due Jun 15, 2026). Phase 2b SUNRISE-PD topline announced; Phase 2 ADDRESS-LC in long COVID ongoing.
BIV201
Stage not disclosed · Active
Indications
Cirrhosis with ascites / refractory ascites(Stage not disclosed)
Status note Liver program. Finalizing Phase 3 protocol design for cirrhosis/ascites following FDA discussions in 2023 and 2025; no Phase 3 trial initiated per this filing.
Per-asset detail extracted from the 10-Q filed 2026-05-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.